<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01683123</url>
  </required_header>
  <id_info>
    <org_study_id>get-buf-2010-02</org_study_id>
    <nct_id>NCT01683123</nct_id>
  </id_info>
  <brief_title>Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT</brief_title>
  <acronym>BUFLU</acronym>
  <official_title>Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analyze the results of conditioning with once-daily dose intravenous busulfan and fludarabine
      in patients undergoing HLA identical sibling Allogeneic HSCT for myeloid malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators evaluate a conditioning regimen consisting in Fludarabine 40
      mg/m2 once daily i.v in 60 min. on days -6 to -3 (total dose 160 mg/m2), followed by Busulfan
      3,2 mg/kg once daily i.v. in 180 min. in the same days (total dose 12,8 mg/kg). No busulfan
      pharmacokinetic monitoring is performed. Graft versus host disease prophylaxis consists in
      the combination of cyclosporine and methotrexate. Graft products obtained from bone marrow or
      peripheral blood of HLA identical sibling donors are not manipulated in their cellular
      content before transplantation. Blood products were leukocyte depleted and irradiated before
      transfusion. Supportive care, including seizure prophylaxis, isolation measures, antiemetics,
      antimicrobial agents and growth factors use are followed according to standard procedures.

      The main objectives are to record data regarding engraftment, regimen related toxicity and
      outcome in different patient populations according to age, disease type, disease status at
      HSCT and comorbidities.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">143</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with myeloid malignancies submitted to allogeneic HSCT with an HLA identical sibling
        donor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute Myeloid Leukemia

          -  Myelodysplastic Syndrome

          -  Myeloproliferative Disorders

          -  Chronic Myeloid Leukemia

        Exclusion Criteria:

          -  Performance status ECOG&gt;2

          -  Cardiomyopathy (LVEF &lt;39%)

          -  Pulmonary dysfunction (DLCO&lt;39%)

          -  Hepatic dysfunction Grade &gt;1

          -  Renal dysfunction Grade &gt;1 (Creatinine &gt; 1.6 mg/dl)

          -  HIV infection

          -  Other active neoplasm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier De la Serna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Sanz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</affiliation>
  </overall_official>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2012</study_first_submitted>
  <study_first_submitted_qc>September 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2012</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic HSCT</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

